Left Ventricular Assist Device and Heart Transplantation in Hemophilia A Patient

Richmond VA Medical Center, Ричмонд, Virginia, United States
The Annals of thoracic surgery (Impact Factor: 3.85). 12/2013; 96(6):2245-7. DOI: 10.1016/j.athoracsur.2013.04.095
Source: PubMed


We report here a hemophilia patient who was bridged with a left ventricle assist device and later received heart transplantation. Preparation for surgery with factor VIII supplementation, intraoperative conduct of surgery, and challenges of postoperative course are described with a brief literature review.

7 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background and AimThis study presents the experience of a large Australian hospital in performing cardiac surgery on patients with hereditary bleeding disorders (HBDs) and provides a suggested approach for their perioperative management.Methods Medical records of patients with HBDs who underwent cardiac surgery from January 1997 to December 2013 were reviewed.ResultsSeventeen patients were included in this study, 13 with Hemophilia A, one symptomatic Hemophilia A carrier, one with Hemophilia B, and two with von Willebrand Disease. Cardiac surgical procedures performed included 10 coronary artery bypass graft (CABG) operations, two aortic valve replacements, two mitral valve repairs, two aortic root replacements, and one combined aortic valve replacement and CABG. Perioperative management centered on factor substitution to maintain normal factor levels. Perioperative outcomes including length of hospital stay, mortality, and return to the operating room for bleeding were recorded. Two patients returned to the operating room for bleeding, one patient on the first postoperative day and one patient at day 20 postoperatively with pericardial bleeding.Conclusions Most patients demonstrated excellent hemostasis, suggesting that cardiopulmonary bypass surgery in HBD patients may be safely performed with careful planning.
    Journal of Cardiac Surgery 10/2014; 30(1). DOI:10.1111/jocs.12464 · 0.89 Impact Factor